Abstract

Purpose and Design: To review the current clinical uses, ongoing investigations, and future applications of hematopoietic growth factors. Approved cytokines, as well as cytokines not yet released for general use, are included in this review. Results: Clinical applications of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin, the three recombinant hematopoietic growth factors currently commercially available for clinical use in the United States, are discussed. Macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), PIXY321, stem-cell factor (SCF), IL-1, IL-6, and IL-11 represent cytokines not yet approved; the majority of these newer agents have their principal action at an earlier time point in the hematopoietic cascade than the currently approved cytokines. Current clinical uses of hematopoietic growth factors include decreasing cytopenias associated with chemotherapy, those due to congenital or acquired bone marrow failure states, those that occur after high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients. Conclusion: Hematopoietic growth factors have made a significant impact on the prevention of infections associated with chemotherapy-induced neutropenia, shortening of neutropenia following high-dose chemotherapy and progenitor-cell transplantation, and chemotherapy-associated anemia. Cost- effectiveness and cost-benefit analyses in future phase III and pharmacologic studies will aid in the assessment of these agents.

Original languageEnglish (US)
Pages (from-to)1023-1035
Number of pages13
JournalJournal of Clinical Oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 1995

Fingerprint

Intercellular Signaling Peptides and Proteins
Drug Therapy
Cytokines
Neutropenia
Cost-Benefit Analysis
Interleukin-11
Stem Cell Factor
Macrophage Colony-Stimulating Factor
Interleukin-3
Cell Transplantation
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Erythropoietin
Bone Marrow Transplantation
Interleukin-1
Anemia
Interleukin-6
Patient Care
Leukemia
Stem Cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical applications of hematopoietic growth factors. / Vose, Julie Marie; Armitage, James Olen.

In: Journal of Clinical Oncology, Vol. 13, No. 4, 04.1995, p. 1023-1035.

Research output: Contribution to journalReview article

@article{27f08f804ce740cc8c260e424a298f1d,
title = "Clinical applications of hematopoietic growth factors",
abstract = "Purpose and Design: To review the current clinical uses, ongoing investigations, and future applications of hematopoietic growth factors. Approved cytokines, as well as cytokines not yet released for general use, are included in this review. Results: Clinical applications of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin, the three recombinant hematopoietic growth factors currently commercially available for clinical use in the United States, are discussed. Macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), PIXY321, stem-cell factor (SCF), IL-1, IL-6, and IL-11 represent cytokines not yet approved; the majority of these newer agents have their principal action at an earlier time point in the hematopoietic cascade than the currently approved cytokines. Current clinical uses of hematopoietic growth factors include decreasing cytopenias associated with chemotherapy, those due to congenital or acquired bone marrow failure states, those that occur after high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients. Conclusion: Hematopoietic growth factors have made a significant impact on the prevention of infections associated with chemotherapy-induced neutropenia, shortening of neutropenia following high-dose chemotherapy and progenitor-cell transplantation, and chemotherapy-associated anemia. Cost- effectiveness and cost-benefit analyses in future phase III and pharmacologic studies will aid in the assessment of these agents.",
author = "Vose, {Julie Marie} and Armitage, {James Olen}",
year = "1995",
month = "4",
doi = "10.1200/JCO.1995.13.4.1023",
language = "English (US)",
volume = "13",
pages = "1023--1035",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Clinical applications of hematopoietic growth factors

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 1995/4

Y1 - 1995/4

N2 - Purpose and Design: To review the current clinical uses, ongoing investigations, and future applications of hematopoietic growth factors. Approved cytokines, as well as cytokines not yet released for general use, are included in this review. Results: Clinical applications of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin, the three recombinant hematopoietic growth factors currently commercially available for clinical use in the United States, are discussed. Macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), PIXY321, stem-cell factor (SCF), IL-1, IL-6, and IL-11 represent cytokines not yet approved; the majority of these newer agents have their principal action at an earlier time point in the hematopoietic cascade than the currently approved cytokines. Current clinical uses of hematopoietic growth factors include decreasing cytopenias associated with chemotherapy, those due to congenital or acquired bone marrow failure states, those that occur after high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients. Conclusion: Hematopoietic growth factors have made a significant impact on the prevention of infections associated with chemotherapy-induced neutropenia, shortening of neutropenia following high-dose chemotherapy and progenitor-cell transplantation, and chemotherapy-associated anemia. Cost- effectiveness and cost-benefit analyses in future phase III and pharmacologic studies will aid in the assessment of these agents.

AB - Purpose and Design: To review the current clinical uses, ongoing investigations, and future applications of hematopoietic growth factors. Approved cytokines, as well as cytokines not yet released for general use, are included in this review. Results: Clinical applications of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin, the three recombinant hematopoietic growth factors currently commercially available for clinical use in the United States, are discussed. Macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), PIXY321, stem-cell factor (SCF), IL-1, IL-6, and IL-11 represent cytokines not yet approved; the majority of these newer agents have their principal action at an earlier time point in the hematopoietic cascade than the currently approved cytokines. Current clinical uses of hematopoietic growth factors include decreasing cytopenias associated with chemotherapy, those due to congenital or acquired bone marrow failure states, those that occur after high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients. Conclusion: Hematopoietic growth factors have made a significant impact on the prevention of infections associated with chemotherapy-induced neutropenia, shortening of neutropenia following high-dose chemotherapy and progenitor-cell transplantation, and chemotherapy-associated anemia. Cost- effectiveness and cost-benefit analyses in future phase III and pharmacologic studies will aid in the assessment of these agents.

UR - http://www.scopus.com/inward/record.url?scp=0028912425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028912425&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.4.1023

DO - 10.1200/JCO.1995.13.4.1023

M3 - Review article

C2 - 7535842

AN - SCOPUS:0028912425

VL - 13

SP - 1023

EP - 1035

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -